Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease.
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2012
At a glance
- Drugs Colchicine (Primary)
- Indications Gout
- Focus Pharmacokinetics
- Sponsors URL Pharma
- 11 Oct 2012 Actual initiation date changed from Mar 2010 to May 2010 as reported by ClinicalTrials.gov.
- 08 Mar 2012 Trial phase changed from I to IV as reported by ClinicalTrials.gov.
- 18 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.